Esophageal cancer is one of the most aggressive malignancies worldwide, ranking as the sixth leading cause of cancer-related deaths globally, according to the World Health Organization (WHO). Advances in molecular science have opened a new era in which biomarker-driven strategies allow clinicians to move beyond one-size-fits-all approaches and tailor treatment to each patient’s tumor profile.
Key Takeaways
- Esophageal cancer is among the deadliest cancers globally, making precise treatment selection critical.
- Molecular biomarkers such as HER2, PD-L1, VEGFR, and FGFR2b guide targeted and immunotherapy decisions.
- HER2 overexpression and PD-L1 expression are the most clinically established biomarkers in esophageal cancer management.
- Biomarker testing—through tissue biopsy or liquid biopsy—is now an essential step in the diagnostic and treatment-planning process.
- Personalized treatment strategies based on biomarker profiles improve outcomes while reducing unnecessary toxicity.
Key Molecular Biomarkers Used in Esophageal Cancer Therapy
Esophageal cancer molecular biomarkers are measurable biological indicators found within or on tumor cells that reflect the genetic and molecular characteristics driving cancer growth. Identifying these markers allows oncologists to understand how a specific tumor behaves and which therapeutic pathways are most likely to be effective. This represents a fundamental shift from empirical chemotherapy toward precision oncology.
Several biomarkers have emerged as clinically relevant in esophageal cancer. Human epidermal growth factor receptor 2 (HER2) amplification or overexpression is detected in approximately 15–20% of esophageal adenocarcinoma cases. Programmed death-ligand 1 (PD-L1) expression is evaluated using the combined positive score (CPS), with higher CPS values correlating with improved response to immune checkpoint inhibitors. Other significant markers include vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 2b (FGFR2b), and mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status.
Tumor mutational burden (TMB) is an emerging biomarker that quantifies the number of somatic mutations per megabase of tumor DNA. High TMB may predict stronger immune responses to checkpoint inhibitor therapy. Claudin 18.2, a tight junction protein overexpressed in a subset of gastroesophageal junction tumors, is also under active clinical investigation. Taken together, these molecular targets form the foundation of biomarker-driven esophageal cancer care.
| Biomarker | Prevalence in Esophageal Cancer | Associated Therapy Type |
|---|---|---|
| HER2 | ~15–20% (adenocarcinoma) | Anti-HER2 targeted therapy |
| PD-L1 (CPS ≥ 10) | Variable; ~30–50% with high CPS | Immune checkpoint inhibitors |
| FGFR2b | ~5–10% | FGFR-targeted therapy |
| dMMR / MSI-H | ~5% of esophageal cancers | Immunotherapy (pembrolizumab) |
| TMB-High | Subset of cases | Immunotherapy |
HER2 and PD-L1 Targeted Treatment Options for Esophageal Cancer
HER2 and PD-L1 biomarkers in esophageal cancer represent the two most established molecular targets in current clinical practice. HER2 is a receptor tyrosine kinase that, when overexpressed, promotes uncontrolled cell proliferation. Trastuzumab, a monoclonal antibody targeting HER2, has been approved as a first-line treatment in combination with chemotherapy for HER2-positive esophageal adenocarcinoma. Clinical trial data demonstrated that adding trastuzumab to standard chemotherapy significantly extended median overall survival in this patient subgroup, establishing HER2 as a definitive actionable target.
PD-L1 is a protein expressed on tumor cells that suppresses immune activity by binding to PD-1 receptors on T-cells. When PD-L1 expression is high—particularly with a CPS of 10 or greater—tumors are more likely to respond to immune checkpoint inhibitors such as nivolumab and pembrolizumab. These agents block the PD-1/PD-L1 interaction, effectively releasing the immune system’s ability to recognize and destroy cancer cells. Regulatory approvals for first-line use of immune checkpoint inhibitors in esophageal squamous cell carcinoma and adenocarcinoma are now well established in multiple jurisdictions, including the United States.
Beyond these two primary targets, targeted therapy for esophageal cancer by biomarker continues to expand. Ramucirumab, a VEGFR2-targeted antibody, is approved for second-line treatment in certain patients. Bemarituzumab, which targets FGFR2b, has shown promise in early-phase trials for patients whose tumors overexpress this marker. The field is progressing rapidly, and ongoing studies are exploring combinations of anti-HER2 agents with immunotherapy to enhance efficacy in biomarker-selected populations.
Nivolumab and Pembrolizumab in Practice
Nivolumab has received approval for use in combination with chemotherapy as a first-line regimen for advanced esophageal squamous cell carcinoma, regardless of PD-L1 status in some protocols, while pembrolizumab is indicated specifically in patients with PD-L1 CPS ≥ 10. Both agents have demonstrated improved overall survival compared with chemotherapy alone in phase III trials. Clinicians select between these agents based on tumor histology, PD-L1 CPS, and institutional treatment guidelines.
Emerging Anti-HER2 Combinations
Second-generation anti-HER2 agents and antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan, are showing significant activity in HER2-positive esophageal tumors that have progressed after first-line therapy. ADCs deliver cytotoxic payloads directly to HER2-expressing cells, minimizing systemic toxicity. These developments represent an important next step in biomarker-matched treatment strategies for patients with HER2 amplification.
Biomarker Testing Process and Its Role in Diagnosis
Biomarker testing for esophageal cancer diagnosis is the process of analyzing tumor tissue or blood samples to identify specific molecular characteristics that guide treatment selection. This testing is typically performed following an initial endoscopic biopsy and histopathological confirmation of malignancy. The results directly influence whether a patient is eligible for targeted therapy, immunotherapy, or standard chemotherapy.
The most common testing methods include immunohistochemistry (IHC), which evaluates protein expression such as HER2 and PD-L1, and fluorescence in situ hybridization (FISH), which detects gene amplification. Next-generation sequencing (NGS) offers a comprehensive molecular profile of the tumor, identifying mutations, amplifications, and alterations across multiple genes simultaneously. Liquid biopsy—analysis of circulating tumor DNA (ctDNA) in blood—is an emerging complementary tool, particularly useful for monitoring treatment response and detecting resistance mutations over time.
Standardized testing protocols are essential for reliable results. PD-L1 CPS scoring, for example, must be performed using validated assays and interpreted by trained pathologists, as scoring variability can influence treatment eligibility. Similarly, HER2 testing guidelines recommend repeat FISH testing when IHC results are equivocal (IHC 2+). Early and comprehensive biomarker profiling at the time of diagnosis ensures that no targetable alteration is missed, maximizing therapeutic options for each patient.
Personalized Treatment Decisions Based on Esophageal Cancer Biomarkers
Personalized treatment for esophageal cancer biomarkers refers to a clinical strategy in which therapy is selected and sequenced based on the specific molecular profile of an individual patient’s tumor rather than histology or stage alone. This approach reduces exposure to ineffective therapies, limits unnecessary side effects, and improves the probability of meaningful clinical benefit. As biomarker data become central to treatment algorithms, multidisciplinary tumor boards increasingly rely on molecular findings to guide decision-making.
Esophageal cancer biomarker-based treatment options are structured around the patient’s biomarker profile at diagnosis. A patient with HER2-positive disease will receive an anti-HER2 regimen from the outset. A patient with high PD-L1 CPS and HER2-negative status may be prioritized for immunotherapy in combination with chemotherapy. For patients whose tumors harbor dMMR or MSI-H status, pembrolizumab monotherapy is a recognized option regardless of PD-L1 expression level.
The integration of biomarkers used in esophageal cancer therapy into clinical decision-making also extends to monitoring and adaptation over time. As tumors evolve under treatment pressure, resistance mechanisms may emerge, including HER2 loss or acquisition of new mutations. Serial biomarker assessment through liquid biopsy or repeat tissue sampling allows clinicians to detect these changes early and adjust the treatment strategy accordingly. This dynamic, iterative approach represents the practical application of precision oncology in esophageal cancer care.
- HER2-positive tumors: First-line trastuzumab plus chemotherapy; consider ADCs at progression.
- PD-L1 CPS ≥ 10: Immunotherapy-based first-line regimens are preferred.
- dMMR / MSI-H: Pembrolizumab monotherapy may be appropriate regardless of PD-L1 CPS.
- FGFR2b overexpression: Emerging eligibility for FGFR-targeted agents in clinical trial settings.
- TMB-High: Potential eligibility for tumor-agnostic immunotherapy approvals.
Ultimately, biomarker-driven care requires close coordination between pathologists, medical oncologists, radiation oncologists, and genomic specialists. As the evidence base continues to grow, the expectation is that esophageal cancer management will become increasingly precise, with each treatment decision anchored in the molecular biology of the individual tumor.
Frequently Asked Questions
Which biomarkers are most important for guiding esophageal cancer treatment?
HER2 and PD-L1 are currently the most clinically actionable biomarkers in esophageal cancer. HER2 overexpression, found in roughly 15–20% of adenocarcinomas, directs the use of trastuzumab-based regimens. PD-L1, evaluated by combined positive score, determines eligibility for immune checkpoint inhibitors such as nivolumab and pembrolizumab. Additional markers including dMMR/MSI-H, FGFR2b, and TMB are increasingly tested to expand personalized treatment options.
Is biomarker testing performed at the time of initial esophageal cancer diagnosis?
Yes, biomarker testing is ideally performed immediately after histopathological confirmation of esophageal cancer. Testing on the initial biopsy sample using immunohistochemistry, FISH, or next-generation sequencing allows clinicians to identify targetable alterations before initiating treatment. Early profiling ensures that no patient misses an opportunity for biomarker-matched therapy. In some cases, repeat testing may be recommended if the tumor progresses or if resistance to initial therapy develops.
Can biomarker-based treatments be used alongside standard chemotherapy?
In many cases, yes. Both trastuzumab for HER2-positive disease and immune checkpoint inhibitors for PD-L1–high or histology-appropriate tumors are approved in combination with platinum-based chemotherapy as first-line regimens. The combination approach has demonstrated superior overall survival compared to chemotherapy alone in landmark clinical trials. The specific regimen depends on the patient’s biomarker status, performance status, and tumor histology, and should be determined by a multidisciplinary oncology team.
